Please login to the form below

Not currently logged in
Email:
Password:

Novartis drug works in secondary progressive MS

Novartis dayOrally-active siponimod reduces risk of disability progression

FDA knocks back Amgen's chronic kidney disease treatment

Amgen flagParsabiv was hoped to equal or exceed solid earner Sensipar

Surging sales of Lundbeck's CNS drugs assist recovery

Lundbeck HQTwo newer antidepressants help boost sales after Cipralex patent ends

AZ slims down again with sale of antibiotics to Pfizer

AstraZeneca AZ global R&D corporate HQDeal does not include biologic anti-infective products from Medimmune unit

AbbVie's venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

NICE backs Xalkori for lung cancer, but cuts two others from CDF

Preliminary verdict removes Novartis' Afinitor and Janssen's Imbruvica

Gilead's Truvada cleared for HIV prevention in EU

Gilead SciencesMay help slow down recent uptick in new HIV diagnoses

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AstraZeneca AZAMARANTH could be first treatment to target underlying mechanism

Immunotherapy and future directions in oncology

How the field of cancer drugs is expanding as technology improves

Latest appointments

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Serviceplan Health & Life

We are your creative global lead agency, your Pan-European hub and your worldwide network....

Latest intelligence

A stumble, but not a fall – what’s next for Opdivo?
Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results....
Blog: A new 'At your service' model for pharma
Turning the traditional sales model on its head to deliver commercial outcomes without selling at all...
london-conferences-anthill.jpg
Meet Anthill at conferences in London
October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit...

Infographics